Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 54, 2019 - Issue 4
Submit an article Journal homepage
2,020
Views
42
CrossRef citations to date
0
Altmetric
Review

Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

Davide Giuseppe RibaldoneDepartment of Surgical Sciences, University of Turin, Turin, Italy; Correspondence[email protected]
,
Rinaldo PellicanoMolinette Hospital, Unit of Gastroenterology, Turin, Italy;
,
Marta VerneroFirst Department of Internal Medicine, IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy;
,
Gian Paolo CavigliaDepartment of Medical Sciences, University of Turin, Turin, ItalyORCID Iconhttp://orcid.org/0000-0002-0529-9481
ORCID Icon,
Giorgio Maria SaraccoDepartment of Medical Sciences, University of Turin, Turin, Italy
,
Mario MorinoDepartment of Surgical Sciences, University of Turin, Turin, Italy;
&
Marco AstegianoMolinette Hospital, Unit of Gastroenterology, Turin, Italy;
show all
Pages 407-413 | Received 06 Feb 2019, Accepted 14 Mar 2019, Published online: 04 Apr 2019

Citations (42)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yasmina E. Hernandez Santana, Naoise Irwin & Patrick T. Walsh. (2022) IL-36: a therapeutic target for ulcerative colitis?. Expert Opinion on Therapeutic Targets 26:6, pages 507-512.
Read now

Articles from other publishers (41)

John K Triantafillidis, Constantinos G Zografos, Manousos M Konstadoulakis & Apostolos E Papalois. (2024) Combination treatment of inflammatory bowel disease: Present status and future perspectives. World Journal of Gastroenterology 30:15, pages 2068-2080.
Crossref
Malcolm Irani & Bincy Abraham. (2024) Choosing Therapy for Moderate to Severe Crohn’s Disease. Journal of the Canadian Association of Gastroenterology 7:1, pages 1-8.
Crossref
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, I. A. Li, E. A. Sabelnikova, T. . Shkurko, B. A. Nanaeva, T. A. Baranova & M. Yu. Timanovskaya. (2024) Efficacy and safety of dual therapy - biological and small molecules in patients with ulcerative colitis. Experimental and Clinical Gastroenterology:9, pages 5-12.
Crossref
Saurabh Mehandru, Jean-Frederic Colombel, Julius Juarez, James Bugni & James O. Lindsay. (2023) Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease. Mucosal Immunology 16:6, pages 859-870.
Crossref
Cristina Valero-Martínez, Judit Font Urgelles, Meritxell Sallés, Beatriz E. Joven-Ibáñez, Alexia de Juanes, Julio Ramírez, Xavier Juanola, Raquel Almodóvar, Ana Laiz, Mireia Moreno, Manel Pujol, Emma Beltrán, José Antonio Pinto-Tasende, Laura Crespí, Luis Sala-Icardo, Santos Castañeda & Rosario García-Vicuña. (2023) Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Frontiers in Immunology 14.
Crossref
Jean-Frederic Colombel, Ryan C. Ungaro, Bruce E. Sands, Corey A. Siegel, Douglas C. Wolf, John F. Valentine, Brian G. Feagan, Blue Neustifter, Harisha Kadali, Pradeep Nazarey, Alexandra James, Vipul Jairath & Rana M. Qasim Khan. (2023) Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER). Clinical Gastroenterology and Hepatology.
Crossref
Alessandro Massano, Luisa Bertin, Fabiana Zingone, Andrea Buda, Pierfrancesco Visaggi, Lorenzo Bertani, Nicola de Bortoli, Matteo Fassan, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Cristina Bezzio, Valentina Casini, Davide Giuseppe Ribaldone, Edoardo Vincenzo Savarino & Brigida Barberio. (2023) Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review. Cancers 15:15, pages 3824.
Crossref
Natalie Li, Rupert Leong & Peter Youssef. (2023) Combination non tumour necrosis factor biologic and small‐molecule therapy in a patient with ankylosing spondylitis and Crohn disease . Internal Medicine Journal 53:6, pages 1083-1084.
Crossref
Elliot M. Berinstein, Jessica L Sheehan, Janson Jacob, Calen A. Steiner, Ryan W. Stidham, Carol Shannon, Shrinivas Bishu, Jake Levine, Shirley A. Cohen-Mekelburg, Akbar K. Waljee, Peter D. R. Higgins & Jeffrey A. Berinstein. (2023) Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. Digestive Diseases and Sciences 68:6, pages 2604-2623.
Crossref
Matthew D McCormack, Natasha A Wahedna, David Aldulaimi & Peter Hawker. (2023) Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World Journal of Clinical Cases 11:12, pages 2621-2630.
Crossref
Lei Li, Peilan Peng, Ning Ding, Wenhui Jia, Canhua Huang & Yong Tang. (2023) Oxidative Stress, Inflammation, Gut Dysbiosis: What Can Polyphenols Do in Inflammatory Bowel Disease?. Antioxidants 12:4, pages 967.
Crossref
Eric Cheah & James Guoxian Huang. (2023) Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World Journal of Gastroenterology 29:10, pages 1539-1550.
Crossref
Eric Cheah & James Guoxian Huang. (2023) Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World Journal of Gastroenterology 29:10, pages 1395-1406.
Crossref
Monica State & Lucian Negreanu. (2023) Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review. Biomedicines 11:2, pages 544.
Crossref
Zelin Feng, Guangbo Kang, Jiewen Wang, Xingjie Gao, Xiaoli Wang, Yulin Ye, Limin Liu, Jingwen Zhao, Xinjuan Liu, He Huang & Xiaocang Cao. (2023) Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies. Biomedicine & Pharmacotherapy 158, pages 114174.
Crossref
Hae Chan Lee, Yiyoung Kwon, Eun Sil Kim, Soomin Ahn, Yon Ho Choe & Mi Jin Kim. (2023) Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum. Annals of Dermatology 35.
Crossref
Mariam Malik, Bryony Jones, Emma Williams, Ramesh Kurukulaaratchy, Chris Holroyd & Alice Mason. (2023) Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series. Rheumatology Advances in Practice 7:1.
Crossref
Domingo Balderramo. (2022) Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease. World Journal of Gastroenterology 28:47, pages 6743-6751.
Crossref
Magdalena Wlazło, Monika Meglicka, Anna Wiernicka, Marcin Osiecki & Jarosław Kierkuś. (2022) Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study. Children 10:1, pages 11.
Crossref
Israa Abdullah, Khaled AlMojil & Mohammad Shehab. (2022) Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease. Diseases 10:4, pages 102.
Crossref
Alexandra S. HudsonPatricia AlmeidaHien Q. Huynh. (2022) Dual Biologic Therapy in a Patient With Niemann-Pick Type C and Crohn Disease: A Case Report and Literature Review. JPGN Reports 3:3, pages e225.
Crossref
Shivali Berera, Stephanie C Ioannou, Diana Morillo, Alejandro M A Mantero, Judith Pignac-Kobinger, Niurka Colina, Ana M Santander, Irina Fernandez, Maria Alejandra Quintero, Jennifer Rodriguez, David H Kerman, Oriana M Damas, Frank Czul, Daniel A Sussman, Maria T Abreu & Amar R Deshpande. (2022) Combining Pentoxifylline With Vedolizumab for Crohn’s Disease: Results of a Randomised, Placebo-controlled Pilot Study. Journal of Crohn's and Colitis.
Crossref
Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn & Peter Laszlo Lakatos. (2022) The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials. Journal of Clinical Medicine 11:11, pages 3045.
Crossref
Giuseppe Losurdo, Antonietta Gerarda Gravina, Luca Maroni, Enrico Maria Gabrieletto, Gianluca Ianiro, Alberto Ferrarese, Alessia Visintin, Leonardo Frazzoni, Gaia Pellegatta, Anna Sessa, Loris Lopetuso & Serena Porcari. (2022) Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease 54:5, pages 583-597.
Crossref
Michael Au, Nikola Mitrev, Rupert W Leong & Viraj Kariyawasam. (2022) Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World Journal of Clinical Cases 10:8, pages 2569-2576.
Crossref
Waseem Ahmed, Jonathan Galati, Anand Kumar, Paul J. Christos, Randy Longman, Dana J. Lukin, Ellen Scherl & Robert Battat. (2022) Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 20:3, pages e361-e379.
Crossref
Shivali Berera & Gary R. Lichtenstein. (2022) Novel Therapies for Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology 20:1, pages 81-100.
Crossref
Eduard Brunet Mas & Xavier Calvet Calvo. (2022) Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients. Journal of Clinical Medicine 11:4, pages 1076.
Crossref
Waseem Ahmed. (2022) Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease. Crohn's & Colitis 360 4:1.
Crossref
Quazim A Alayo, Marc Fenster, Osama Altayar, Kerri L Glassner, Ernesto Llano, Kindra Clark-Snustad, Anish Patel, Lukasz Kwapisz, Andres J Yarur, Benjamin L Cohen, Matthew A Ciorba, Deborah Thomas, Scott D Lee, Edward V LoftusJr.Jr., David I Fudman, Bincy P Abraham, Jean-Frederic Colombel & Parakkal Deepak. (2022) Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohn's & Colitis 360 4:1.
Crossref
Mahnur Haider & Bret Lashner. (2021) Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 55:8, pages 661-666.
Crossref
Duke Geem & Subra Kugathasan. (2021) It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 27:8, pages 1361-1362.
Crossref
Ernesto M Llano, Shreeju Shrestha, Ezra Burstein, Moheb Boktor & David I Fudman. (2021) Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease. Crohn's & Colitis 360 3:3.
Crossref
Giuseppe Privitera, Daniela Pugliese, Sara Onali, Valentina Petito, Franco Scaldaferri, Antonio Gasbarrini, Silvio Danese & Alessandro Armuzzi. (2021) Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmunity Reviews 20:6, pages 102832.
Crossref
Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino, Anna Viola, Davide Giuseppe Ribaldone, Andrea Buda, Cristina Bezzio, Gionata Fiorino, Massimo Claudio Fantini, Franco Scaldaferri, Luisa Guidi, Silvio Danese, Antonio Gasbarrini, Ambrogio Orlando & Alessandro Armuzzi. (2021) Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis 15:2, pages 335-339.
Crossref
Prasanta Debnath & Pravin M. Rathi. (2021) Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflammatory Intestinal Diseases 6:1, pages 1-17.
Crossref
Giuseppe Biscaglia, Mariano Piazzolla, Francesco Cocomazzi, Gennaro Melchionda, Angelo De Cata, Fabrizio Bossa, Orazio Palmieri & Angelo Andriulli. (2020) Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology & Hepatology 32:12, pages 1579-1582.
Crossref
Marisa Iborra, Belén Beltrán, Agnes Fernández‐Clotet, Eva Iglesias‐Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra‐Ausin, Francisco Mesonero, Rocío Ferreiro‐Iglesias, Joaquín Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos González‐Muñoza, Beatriz Antolín, María González‐Vivo, Ana Y. Carbajo, Santiago García‐López, Albert Martín‐Cardona, Gerard Surís, María Dolores Martin‐Arranz, Ruth de Francisco, Fiorella Cañete, Eugeni Domènech & Pilar Nos. (2020) Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Alimentary Pharmacology & Therapeutics 52:6, pages 1017-1030.
Crossref
Christine Olbjørn, Jon Bergreen Rove & Jørgen Jahnsen. (2020) Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Pediatric Drugs 22:4, pages 409-416.
Crossref
Yon Ho Choe. (2020) Precision medicine for pediatric inflammatory bowel disease: a perspective. Precision and Future Medicine 4:2, pages 43-52.
Crossref
Giovanni Clemente Actis, Rinaldo Pellicano, Sharmila Fagoonee & Davide Giuseppe Ribaldone. (2019) History of Inflammatory Bowel Diseases. Journal of Clinical Medicine 8:11, pages 1970.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.